GSK runners-up get $4M, board seat

So GlaxoSmithKline's dynamic duo is worth $4.1 million each. The two execs passed over for the CEO job--Chris Viehbacher (photo), president of the company's U.S. pharma business; and David Stout (photo), president of pharmaceutical operations--will each get a retention package worth that much if shareholders approve. Most of the package will come in the form of stock options over the next two to three years, with a small amount up front in cash.

You'll recall that, while deciding whom to appoint as its next chief exec, Glaxo put Viehbacher, Stout, and then-European president of pharma Andrew Witty (photo) through their paces. The board chose Witty as CEO-designate, of course, and immediately investors began to worry that Viehbacher and Stout would jump ship, taking their considerable expertise with them. What better way to assure their loyalty than a staged payoff, plus a big say-so on the board?

- read the report from The Telegraph

Related Articles:
GSK CEO also-rans may get on board. Report
At GSK, a public race for the top spot. Report
Just who is Glaxo's Andrew Witty? Report
GSK taps Witty as next CEO. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.